Table 2.
Adjusted mean change in HbA1c (%) from baseline to 12 weeks with vildagliptin 50 mg qd/bid and placebo by racial/ethnic subgroups
| Race/ethnicity | Mean baseline HbA1c | Adjusted mean change from baseline (SE) | Difference in adjusted mean change (Vildagliptin − Placebo) | |||
|---|---|---|---|---|---|---|
| Vildagliptin; placebo, n | Vildagliptin/placebo | Vildagliptin 50 mg qd/bid | Placebo | Mean (SE) | 95% CI | |
| Caucasians | 1340; 939 | 8.3/8.2 | −0.83 (0.02) | −0.14 (0.02) | −0.68 (0.03) 1 | −0.74, −0.63 |
| Asians | 1123; 894 | 8.4/8.5 | −0.96 (0.02) | −0.16 (0.02) | −0.80 (0.03) 1 | −0.86, −0.74 |
| Japanese | 339; 285 | 8.1/8.1 | −0.99 (0.04) | 0.05 (0.04) | −1.04 (0.06) 1 | −1.15, −0.93 |
| Chinese | 529; 387 | 8.4/8.5 | −0.94 (0.03) | −0.27 (0.03) | −0.66 (0.05) 1 | −0.75, −0.57 |
| Indian | 187; 164 | 8.6/8.8 | −1.01 (0.05) | −0.19 (0.05) | −0.82 (0.07) 1 | −0.97, −0.68 |
All values are expressed as % units unless specified.
Abbreviations: bid, twice daily; CI, confidence interval; HbA1c, glycated haemoglobin; qd, once daily; SE, standard error.
1
P < .0001 compared to placebo. P‐value for interaction term = .019.